Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.40 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6739645 | 0.85 | HRH3 (0.40) | HRH3KDM4ETDP1 | |
| SCHEMBL6737935 | 0.75 | RAPGEF3 (0.44) | HRH3RAPGEF3POLB | |
| SCHEMBL6735212 | 0.72 | KAT2B (0.38) | HRH3KMT2AKDM4EMEN1 | |
| SCHEMBL6734314 | 0.72 | HRH3 (0.44) | HRH3POLBKMT2AL3MBTL1KDM4E | |
| SCHEMBL6729982 | 0.72 | HRH3 (0.40) | HRH3RAPGEF3CYP2D6CYP2C9KDM4E | |
| SCHEMBL6734004 | 0.71 | HRH3 (0.67) | HRH3KMT2AMEN1TDP1 | |
| SCHEMBL6733733 | 0.71 | RAPGEF3 (0.39) | HRH3RAPGEF3POLB | |
| SCHEMBL7659514 | 0.71 | RAPGEF3 (0.46) | HRH3RAPGEF3 | |
| SCHEMBL7660195 | 0.69 | HRH3 (0.47) | HRH3RAPGEF3KMT2AKDM4EMEN1 | |
| SCHEMBL7662241 | 0.68 | HRH3 (0.42) | HRH3KDM4EMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-01 | — | — | US | disclosed |
| US-20040122026-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20030225288-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | HRH3 530/4885RAPGEF3 2984/4885ENPP2 1508/4885 |
| US-20030225288-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | HRH3 530/4885RAPGEF3 2984/4885ENPP2 1508/4885 |
| US-20040122026-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | HRH3 530/4885RAPGEF3 2984/4885ENPP2 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.